Pages that link to "Q44205583"
Jump to navigation
Jump to search
The following pages link to Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant (Q44205583):
Displaying 50 items.
- Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants (Q27025822) (← links)
- Interferons and viruses: an evolutionary arms race of molecular interactions (Q28083788) (← links)
- Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project (Q30243961) (← links)
- Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection (Q30387896) (← links)
- A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. (Q30423922) (← links)
- Mycobacterium tuberculosis Rv3586 (DacA) is a diadenylate cyclase that converts ATP or ADP into c-di-AMP. (Q31058151) (← links)
- Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge (Q34070683) (← links)
- Cyclic GMP-AMP displays mucosal adjuvant activity in mice (Q34309082) (← links)
- STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes (Q35082223) (← links)
- The mucosal adjuvant cyclic di-AMP exerts immune stimulatory effects on dendritic cells and macrophages (Q35154923) (← links)
- The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo (Q35595683) (← links)
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity (Q35634752) (← links)
- Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. (Q35836140) (← links)
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade (Q35858368) (← links)
- Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17 Th1 specific immune responses and confers protection against Trypanosoma cruzi (Q36289461) (← links)
- Cyclic dinucleotides and the innate immune response (Q37597305) (← links)
- Cyclic di-nucleotides: new era for small molecules as adjuvants. (Q37940637) (← links)
- Modulating immunity as a therapy for bacterial infections (Q37994068) (← links)
- Systematic identification of small molecule adjuvants (Q38020881) (← links)
- Biofilm infections, their resilience to therapy and innovative treatment strategies (Q38048367) (← links)
- Optimizing efficacy of mucosal vaccines. (Q38059754) (← links)
- Adjuvant immunotherapies as a novel approach to bacterial infections (Q38096056) (← links)
- Cyclic di-AMP: another second messenger enters the fray (Q38118107) (← links)
- Interferon regulatory factor 3 in adaptive immune responses. (Q38216206) (← links)
- Intranasal formulations: promising strategy to deliver vaccines (Q38223050) (← links)
- Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies (Q38461061) (← links)
- Cytosolic sensing of aberrant DNA: arming STING on the endoplasmic reticulum (Q38556467) (← links)
- Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway (Q38654647) (← links)
- New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy (Q38883770) (← links)
- STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment (Q38949322) (← links)
- Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems (Q39384289) (← links)
- Cyclic Dinucleotides in the Scope of the Mammalian Immune System (Q40339226) (← links)
- Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice (Q42369088) (← links)
- Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins. (Q43170567) (← links)
- Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization. (Q47169865) (← links)
- cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue (Q47170879) (← links)
- A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination (Q47573396) (← links)
- Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes (Q47863497) (← links)
- Cyclic dinucleotides modulate human T-cell response through monocyte cell death (Q50702516) (← links)
- STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection. (Q52714689) (← links)
- MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo. (Q54487555) (← links)
- STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice. (Q55399721) (← links)
- Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids. (Q55405632) (← links)
- Stimulator of Interferon Genes in Classical Dendritic Cells Controls Mucosal Th17 Responses to Cyclic Dinucleotides for Host Defenses Against Microbial Infections in Gut. (Q55412846) (← links)
- B Cell-Intrinsic STING Signaling Triggers Cell Activation, Synergizes with B Cell Receptor Signals, and Promotes Antibody Responses (Q57038239) (← links)
- Genetic Engineering of Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype (Q58764447) (← links)
- The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization (Q64229218) (← links)
- Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development (Q89472144) (← links)
- Selective Loss of Responsiveness to Exogenous but Not Endogenous Cyclic-Dinucleotides in Mice Expressing STING-R231H (Q90176744) (← links)
- The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells (Q91999288) (← links)